Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines

Annals of Pharmacotherapy

Volumn 44, Issue 2, 2010, Pages 360-366

  Gales, Barry J ^a,b   Bailey, Emilee K ^c   Reed, Ashley N ^d   Gales, Mark A ^a  

^a SOUTHWESTERN OKLAHOMA STATE UNIVERSITY   (United States)

^b INTEGRIS BAPTIST MEDICAL CENTER   (United States)

^c Salisbury Pharmacy   (United States)

^d Wal Mart Stores Inc   (United States)

Author keywords

Angiotensin receptor blocker; Angiotensin converting enzyme inhibitor; Headaches; Migraine; Renin angiotensin system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPROSARTAN; IRBESARTAN; LISINOPRIL; LOSARTAN; OLMESARTAN; PLACEBO; TASOSARTAN; TELMISARTAN; TRIPTAN DERIVATIVE; VALSARTAN;

BLOOD PRESSURE; CLINICAL TRIAL; COUGHING; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEADACHE; HUMAN; HYPERTENSION; LOW DRUG DOSE; META ANALYSIS; MIGRAINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STOMACH PAIN; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; CLINICAL TRIALS AS TOPIC; HUMANS; LISINOPRIL; MIGRAINE DISORDERS; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TREATMENT OUTCOME;

EID: 76149125470     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M312     Document Type: Review

References (24)

1. Headache classification subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24(suppl 1):9-160. DOI 10.1111/j.1468-2982.2003.00825.x
2. Stovner LJ, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27:193-210. DOI 10.1111/j.1468-2982.2007.01288.x
3. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American migraine study II. Headache 2001;41:638- 45. DOI 10.1046/j.1526-4610.2001.041007638.x
4. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American migraine study II. Headache 2001;41:646-57. DOI 10.1046/j.1526-4610.2001.041007646.x
5. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2000;55:754-62.
6. Van der Kuy PH, Lohman JJ. A quantification of the placebo response in migraine prophylaxis. Cephalalgia 2002;22:265-70. DOI 10.1046/j.1468-2982.2002. 00363.x
7. Tronvik E, Stovner LJ, Schrader H, Bovim G. Involvement of the reninangiotensin system in migraine. J Hypertens 2006;24(suppl 1):S139- 43. DOI 10.1097/01.hjh.0000220419.86149.11
8. Onder G, Pahor M, Gambassi G, et al. Association between ACE inhibitors use and headache caused by nitrates among hypertensive patients: results from the Italian group of pharmacoepidemiology in the elderly (GIFA). Cephalalgia 2003;23:901-6. DOI 10.1046/j.1468-2982.2003.00627.x
9. Tronvik E, Stovner LJ, Bovim G, et al. Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients. BMC Neurol 2008;8:4. DOI 10.1186/1471-2377-8-4
10. Silberstein S, Tfelt-Hansen P, Dodick DW, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 2008;28:484-95. DOI 10.1111/j.1468-2982.2008.01555.x
11. Rahimtoola H, Buurma H, Tijssen CC, Leufkens HG, Egberts ACG. Reduction in the therapeutic intensity of abortive migraine drug use during ACE inhibition therapy - a pilot study. Pharmacoepidemiol Drug Saf 2004;13:41-7. DOI 10.1002/pds.893
12. Sicuteri F. Enkephalinase inhibition relieves pain syndrome of central dysnociception (migraine and related headache). Cephalalgia 1981;1: 229-32. DOI 10.1046/j.1468-2982.1981.0104229.x
13. Bender WI. ACE inhibitors for prophylaxis of migraine headaches. Headache 1995;35:470-1. DOI 10.1111/j.1526-4610.1995.hed3508470.x
14. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001;322: 19-22. DOI 10.1136/bmj.322.7277.19
15. Schuh-Hofer S, Flach U, Meisel A, Israel H, Reuter U, Arnold G. Efficacy of lisinopril in migraine prophylaxis - an open label study. Eur J Neurol 2007;14:701-3. DOI 10.1111/j.1468-1331.2007.01764.x15
16. Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin II receptor blocker. JAMA 2003;289: 65-9. DOI 10.1001/jama.289.1.65
17. Owada K. Efficacy of candesartan in the treatment of migraine in hypertensive patients. Hypertens Res 2004;27:441-6. DOI 10.1291/hypres.27.441
18. Charles JA, Jotkowitz S, Byrd LH. Prevention of migraine with olmesartan in patients with hypertension/prehypertension. Headache 2006;46: 503-7. DOI 10.1111/j.1526-4610.2006.00382.x
19. Diener HC, Gendolla A, Feuersenger A, et al. Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial. Cephalalgia 2009; 29:921-7. DOI 10.1111/j.1468-2982.2008.01825.x
20. Camarda R, Monastero R, Mannino M, Camarda C. Enalapril prophylaxis for migraine with aura (letter). Headache 2003;43:170. DOI 10.1046/j.1526-4610.2003. 03038.x
21. Etminan M, Levine MAH, Tomlinson G, Rochon PA. Efficacy of angiotensin II receptor antagonists in preventing headache: a systematic overview and meta-analysis. Am J Med 2002;112:642-6. DOI 10.1016/S0002-9343%2802%2901100-2
22. Iwasaki Y, Ikeda K. Olmesartan, migraine, and blood pressure (letter). Headache 2006;46:1309. DOI 10.1111/j.1526-4610.2006.00546-1.x
23. Ahmad S. Losartan and severe migraine (letter). JAMA 1995;274:1266-7. DOI 10.1001/jama.274.16.1266
24. Leinisch-Dahlke E, Schmidt-Wilcke T, Krämer BK, May A. Improvement of dialysis headache after treatment with ACE-inhibitors but not angiotensin II receptor blocker: a case report with pathophysiological considerations. Cephalalgia 2004;25:71- 4. DOI 10.1111/j.1468-2982.204.00804.x